Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2004

View Archived Issues

H3 activation for allergic rhinitis relief

Serotonergic system involved in oleamide sleep-inducing action

IL-6 involved in myocardial dysfunction of meningococcal septic shock

Improved glycemic control found with pioglitazone plus sulfonylureas in type 2 diabetes

Efficacy and safety of subcutaneous insulin and inhaled AERx insulin in type 2 diabetes

Antitumor effects reported for erlotinib in metastatic head and neck cancer

Nestorone in contraception and hormone replacement therapy

Two novel series of prostanoid IP antagonists discovered at Bayer

Exelixis scientists present new antiangiogenic ADAM-10 inhibitors

Novel Rho kinase inhibitors prepared and tested at Bayer

New pyridazine-based PDE4 inhibitors and their use reported by Merck KGaA

New MCH antagonists for obesity and other uses claimed by Abbott

Altana and Signal scientists identify novel PKC-theta inhibitors

Dual JNK/GSK-3 inhibitors under study at Applied Research Systems

Bevacizumab inhibits tumor vascularity

A phase III trial confirms the analgesic effects of Cellegesic in chronic anal fissure

Preliminary phase III results support the use of natalizumab in Crohn's disease

Once-daily tramadol reported to provide 24-hour pain relief in osteoarthritis of the knee

Inconclusive evidence reported on the relationship between statins and fracture risk in older women

NICE issues guidance in clinical management of chronic hepatitis C

Avidex and ChemOvation extend RA collaboration

Preliminary results of phase IIb eculizumab show improvement in ACR20

New phase I trial for RSR-13 in locally advanced NSCLC

Cerus acquires mesothelin rights from Johns Hopkins University

NX-1207 produces significant clinical improvement in BPH

Phase II trials to evaluate VT-111 for ACS

New regulatory submissions for Nexium

Phase III program under way for Viramidine

Beyond Genomics and GlaxoSmithKline enter metabolic disorder collaboration

Pfizer reports significant events during past 12 months and forecasts strong growth platform

First launch for Symbyax

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...